



2024

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Speech Abstract

Topic:

Navigating ADC to Clinical Success with the Learning from Current Research

Abstract

The integration of antibody-drug conjugate (ADC) in breast cancer has improved overall survival and aims to spare some of the toxicity associated with conventional chemotherapy, changing the treatment paradigm significantly. In addition, new targets have been identified that can be exploited for the development of ADCs for breast cancer, including Trop2, HER2, HER3, and so forth. Although ADCs have offered patients with a clinically meaningful benefit, particularly for metastatic disease, there are still challenges that need to be addressed, including the optimization of the therapeutic index, the mechanism of resistance, and whether we can identify patients who will likely benefit most through biomarkers.

Therefore, there is great interest in understanding the myth behind. Simultaneously, strategies to overcome the current challenges are also under investigation. In this session, Prof. Leif Ellisen from Mass General Cancer Center will guide us through the challenges and opportunities in this rapidly evolving field, and how we could navigate ADC to clinical success with the learning from current research.